Intranasal delivery of allergen in a nanoemulsion adjuvant inhibits allergen-specific reactions in mouse models of allergic airway disease.
James R BakerAndrew J RaskyJeffrey J LandersKatarzyna W JanczakTiffanie D TottenNicholas W LukacsJessica J O'KonekPublished in: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2021)
These results demonstrate that suppression of allergic airway inflammation and bronchial hyper-reactivity can be achieved using allergen-specific immunotherapy without significant reductions in allergen-specific IgE and suggest that ILC2 cells may be critical targets for this activity.